| abstract |
The present invention relates to a pharmaceutical composition or an anticancer adjuvant for preventing and treating non-small cell lung cancer comprising a substance that modulates the expression or activity of TM4SF4 (transmembrane 4 L six family member 4). More specifically, by reducing the expression of TM4SF4 in adenocarcinoma of non-small cell lung cancer, by reducing the growth, metastasis and invasive capacity of adenocarcinoma cells, and by increasing the expression of TM4SF4 in non-small cell lung cancer other than adenocarcinoma By identifying the ability to reduce the growth, metastasis and invasion, and radiation resistance of these cells, the present invention relates to the use of an expression or activity modulator of TM4SF4 as an anticancer or anticancer adjuvant for non-small cell lung cancer. |